Payment overview · 2025
General Payments
$225.49
13 reported records · 8 companies
Healthcare provider profile · identity verified
Niranjan Shrestha, M.D., FAAFP
Allopathic & Osteopathic Physicians|Family Medicine · CENTRALIA, IL · NPI 1508031758
Verified facts
What the public records show
CMS Open Payments records show Niranjan Shrestha, M.D., FAAFP received $225.49 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.97 | 17.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.61 | 15.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.35 | 14.8% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $32.79 | 14.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.56 | 13.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.27 | 9.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.98 | 8.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.96 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.51 | 12 |
| Long term medical supply or device loan | $19.98 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.35 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1314 | 253 |
| Omeprazole | Omeprazole | 898 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 685 | 115 |
| Gabapentin | Gabapentin | 489 | 80 |
| Sertraline Hcl | Sertraline Hcl | 469 | 89 |
| Metformin Hcl Er | Metformin Hcl | 407 | 89 |
| Furosemide | Furosemide | 404 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 64 |
| Tramadol Hcl | Tramadol Hcl | 370 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 368 | 68 |
| Trazodone Hcl | Trazodone Hcl | 345 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 337 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 71 |
| Montelukast Sodium | Montelukast Sodium | 304 | 63 |
| Potassium Chloride | Potassium Chloride | 300 | 52 |
| Losartan Potassium | Losartan Potassium | 291 | 55 |
| Metformin Hcl | Metformin Hcl | 281 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 49 |
| Lisinopril | Lisinopril | 245 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 187 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 181 | 29 |
| Famotidine | Famotidine | 180 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 177 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 47 |
| Xarelto | Rivaroxaban | 170 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 28 |
| Bupropion Xl | Bupropion Hcl | 167 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 46 |
| Risperidone | Risperidone | 145 | 22 |
| Ozempic | Semaglutide | 143 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 137 | 23 |
| Clonazepam | Clonazepam | 132 | 18 |
| Lamotrigine | Lamotrigine | 129 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 129 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 24 |
| Atenolol | Atenolol | 121 | 24 |
| Allopurinol | Allopurinol | 120 | 22 |
| Levetiracetam | Levetiracetam | 120 | 21 |
| Mirtazapine | Mirtazapine | 117 | 25 |
| Prednisone | Prednisone | 117 | 67 |
| Ezetimibe | Ezetimibe | 115 | 20 |
| Oxcarbazepine | Oxcarbazepine | 113 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 111 | 28 |
| Topiramate | Topiramate | 110 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 108 | 16 |
| Carvedilol | Carvedilol | 105 | 19 |
| Mounjaro | Tirzepatide | 105 | 19 |
| Spironolactone | Spironolactone | 101 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 21 |
| Fenofibrate | Fenofibrate | 91 | 23 |
| Baclofen | Baclofen | 90 | 17 |
| Jardiance | Empagliflozin | 90 | 17 |
| Pregabalin | Pregabalin | 90 | 13 |
| Folic Acid | Folic Acid | 89 | 24 |
| Olanzapine | Olanzapine | 88 | 15 |
| Midodrine Hcl | Midodrine Hcl | 84 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Eliquis | Apixaban | 81 | 14 |
| Linzess | Linaclotide | 81 | 16 |
| Donepezil Hcl | Donepezil Hcl | 79 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 79 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 16 |
| Ondansetron Odt | Ondansetron | 77 | 31 |
| Carbamazepine | Carbamazepine | 69 | 11 |
| Memantine Hcl Er | Memantine Hcl | 68 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 63 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 20 |
| Alprazolam | Alprazolam | 62 | 12 |
| Lacosamide | Lacosamide | 62 | 12 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 59 | suppressed |
| Roflumilast | Roflumilast | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | suppressed |
| Azithromycin | Azithromycin | 56 | 46 |
| Glimepiride | Glimepiride | 56 | 14 |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 53 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 11 |
| Lorazepam | Lorazepam | 47 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 32 |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Simvastatin | Simvastatin | 43 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Rybelsus | Semaglutide | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 37 | 12 |
| Latanoprost | Latanoprost | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Lubiprostone | Lubiprostone | 35 | 21 |
| Meloxicam | Meloxicam | 34 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 14 |
| Zonisamide | Zonisamide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Clozapine | Clozapine | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 14 |
| Lithium Carbonate Er | Lithium Carbonate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.49 · 13 records | Novo Nordisk Inc | FARXIGA, FREESTYLE INSULINX, INCEPTIV, MONOFERRIC, MOUNJARO, NURTEC ODT, QULIPTA, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error